Ascendis Pharma (ASND) – PRNewswire
-
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
-
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
-
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
-
ASCENDANT ANNOUNCES APPOINTMENT OF MR. VAL COETZEE AS DIRECTOR OF PROCESS ENGINEERING
-
ASCENDANT RESOURCES ENTERS TENDER PHASE FOR MANDATED LEAD ARRANGER FOR ITS EXPORT CREDIT AGENCY SUPPORTED PROJECT FINANCING AT ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders
-
ASCENDANT RESOURCES EARNS 80% INTEREST IN THE LAGOA SALGADA PROJECT IN PORTUGAL AND FILES FEASIBILITY STUDY
-
ASCENDANT RESOURCES ANNOUNCES POST-TAX NPV8 OF US$147 MILLION AND 39% IRR FROM INITIAL FEASIBILITY STUDY AT ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
ASCENDANT RESOURCES ANNOUNCES DATE OF ANNUAL SHAREHOLDERS' MEETING
-
ASCENDANT ANNOUNCES POTENTIAL EXPORT CREDIT AGENCY SUPPORT FOR PROJECT FINANCE AT ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
ASCENDANT PROVIDES UPDATE FOR ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer
-
ASCENDANT RESOURCES CONFIRMS SALEABLE GRADE CONCENTRATES ACHIEVED FOR COPPER, LEAD AND ZINC WITH STRONG RECOVERIES AND PRECIOUS METAL CREDITS AT ITS LAGOA SALGADA VMS PROJECT, PORTUGAL
-
ASCENDANT PROVIDES AN UPDATE FOR ITS LAGOA SALGADA POLYMETALLIC PROJECT IN PORTUGAL
-
Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
-
VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin
-
Aristea Therapeutics Strengthens its Team with Appointments of Executive Medical Director and Two Clinical Scientists as Clinical Programs Progress
-
BioNJ Honors NJ's Innovators & the Patients Who Inspire Them
-
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
-
BioNJ's Annual Dinner Meeting & Innovation Celebration to Honor New Jersey's Innovators, COVID-19 Heroes and the Patients Who Inspire Them
-
More than 300 Fast-Growing Biopharmas Set the Stage for Launch Success with Veeva Vault PromoMats
-
Purified Cortrophin™ Gel Available Through AllianceRx Walgreens Prime For Patients with Certain Chronic Autoimmune Disorders
-
Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
-
Argus Research Initiates Equity Report Coverage on Ascendant Resources Inc. (TSX: ASND)
-
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
-
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
-
Ventyx Biosciences Appoints Martin D. Auster, M.D. as Chief Financial Officer
-
VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled
-
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
-
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
-
The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis
-
VISEN Pharmaceuticals announces China Phase 3 clinical study initiation for TransCon human growth hormone, the first unmodified long-acting growth hormone in China
Back to ASND Stock Lookup